AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00801411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00801411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT03445117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: a) The educational intervention comprises putting up posters on vaccination in the clinic, as well as provision of a specially designed flyer to the clinic, which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies. b) Reminders to physicians: The flyers will also serve as physical prompts to physicians to encourage vaccination for their patients. Doctors and clinic staff will also be updated on the study protocol and the recommended adult vaccination schedule before commencement of the study.
Study NCT01700283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise education and walking program
Description: 12-week moderate intensity walking program
Study NCT03842436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital pill
Description: Digital pills over encapsulating Truvada
Study NCT03842436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada prescribed with digital pills for PrEP
Study NCT04417400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: medicines use review
Description: The provision of MUR service as defined in the SOP MUR (Slovene Chamber of Pharmacies). It is classified as a type 2a review (PCNE typology) and it is intended for the patients to support them in regular and proper medicines use. MUR is performed based on medication history and information provided by the patient in a purposely scheduled conversation with the pharmacist. Pharmacists must be certified to provide MUR. MUR goal is to identify DRPs and recommend interventions to resolve them. During the MUR interview, the pharmacist completes a working sheet that records information regarding medicines, identified DRPs and recommended interventions. After the MUR interview, patients are provided with a personal medicines card that contains all the information that is needed to support effective and safe medicines use (dosing regimen, taking with/without food, special warnings, recommendations, etc.).
Study NCT00002740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00002740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00002740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00002740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00892515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gas chromatography
Study NCT00892515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study NCT00892515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Study NCT00892515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00892515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Study NCT00892515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiologic testing
Study NCT00892515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Study NCT00892515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Study NCT00892515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dual x-ray absorptometry
Study NCT00892515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Study NCT00892515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: study of high risk factors
Study NCT05128045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEW-R
Description: Eight session class on nutrition, physical activity, diet, and weight management
Study NCT02109445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
Study NCT02109445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
Study NCT02109445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
Study NCT02109445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
Study NCT02109445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
Study NCT02109445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
Study NCT02041052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy as an adjunct to traditional whipple procedure.
Description: Subtotal gastrectomy as an adjunct to traditional whipple procedure.
Study NCT02041052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional whipple procedure
Description: All patients undergoing whipple procedure without risk for pancreaticojejunal anastomosis leakage.
Study NCT01001806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine 0.45%
Description: One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
Study NCT01001806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bromfenac 0.09%
Description: One day pre operative 1 drop BID then 3 doses pre op day of surgery
Study NCT01001806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nepafenac 0.1%
Description: One drop BID, 1 day pre operative and then 3 doses the day of surgery
Study NCT01065714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogel vehicle
Description: Each morning and evening, gently wash the target area with warm water and gently pat dry with soft towel. Once dry place a small amount of Hydrogel vehicle onto the tip of your finger. Place a dab of the Hydrogel vehicle on either the left or right side of the body as instructed. (Do not use Hydrogel vehicle and Eucerin lotion on the same side of the body.)
Study NCT01065714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eucerin Lotion
Description: Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
Study NCT05155930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internal Family Systems (IFS)
Description: Weekly individual psychotherapy
Study NCT02972450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine
Description: The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection.
Study NCT02972450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab
Description: The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection. Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.
Study NCT00839917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)
Description: Single administration of 0.5 mL subcutaneous injection
Study NCT00839917 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R™ II and Varivax™
Description: Single administration of 0.5 mL subcutaneous injection
Study NCT02701946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Robert Jones bandage
Description: Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US)
Study NCT02701946 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non compressive dressing
Description: Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
Study NCT01377415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine 5 mg/ml infusion 2 ml/h 48 h
Study NCT01377415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine 5 mg/ml infusion 2 ml/h 48 h
Study NCT01129336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.
Study NCT01129336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Therapy
Description: Standard Therapy, including chemotherapy and hormonal therapy, was determined at the discretion of the investigator.
Study NCT00821132 — intervention group
Intervention type: OTHER
Intervention: Genetic study of ALS families
Description: Collection and analysis of genetic material, medical and family histories from families with ALS
Study NCT01428674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interpersonal Mindful Compassion with Touch
Description: A practitioner lightly touches the participant on the hands, arms, shoulders, lower legs and feet while extending loving kindness to the participant.
Study NCT01428674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading while extending loving kindness
Description: The practitioner sits in a room with the participant, pretending to read, while extending loving kindness to the participant.
Study NCT02589041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraneural sciatic nerve injection
Description: A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology.~A baseline and postoperative electrophysiological study will assess the presence of any neurological complication.
Study NCT02589041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1%
Study NCT03634137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide Group 1
Description: One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
Study NCT03634137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide Group 2
Description: One 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
Study NCT04345198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adrenal Artery Ablation
Description: Intervention with adrenal artery ablation is performed in PA patients with resistant hypertension.
Study NCT00436176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Chronic Care Model
Description: Intervention clinicians receive monthly performance feedback reports, cultural competency training, and health navigation training.
Study NCT03988010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Sulfate
Description: 200mg/500ml i.v. solution for infusion
Study NCT03988010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for amantadine sulphate)
Description: 500 cc 0.9% sodium chloride
Study NCT03019120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 1. Subjects will undergo a cognitive evaluation using the Montreal Cognitive Assessment (MoCA) screening test and the Neurotrax computerized cognitive assessment battery.~2. Subjects will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months.~3. Levels of serum calcium will be repeated monthly (end of month 1, 2, 3).~4. Subjects will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~5. At 3-month follow-up subjects will be asked to complete the Neurotrax computerized cognitive assessment battery.
Study NCT01933503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 5 mg
Study NCT01933503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 10 mg
Study NCT01933503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 25 mg
Study NCT01622348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMO-3100 at 0.16 mg/kg
Description: IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
Study NCT01622348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline for Injection
Description: Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
Study NCT01622348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMO-3100 at 0.32 mg/kg
Description: IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
Study NCT02341456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.
Study NCT02341456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is a mitotic inhibitor used in cancer chemotherapy ; it and docetaxel represent the taxane family of drugs.
Study NCT02341456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
Study NCT02484560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell
Study NCT02456974 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
Study NCT02456974 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.
Study NCT02456974 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling in patients receiving vancomycin as part of routine clinical care.
Study NCT02456974 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling in patients receiving teicoplanin as part of routine clinical care.
Study NCT02456974 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling in patients receiving meropenem as part of routine clinical care.
Study NCT02456974 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.
Study NCT02456974 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling in patients receiving amikacin as part of routine clinical care.
Study NCT04202744 — intervention group
Intervention type: OTHER
Intervention: Shoulder and core evaluations
Description: Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated.
Study NCT03312179 — intervention group
Intervention type: DEVICE
Intervention: PCI and DES stenting
Description: Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.
Study NCT03312179 — intervention group
Intervention type: DRUG
Intervention: Incretins
Description: Patients treated before study enrollment by incretin drugs (6 months drugs exposure)
Study NCT04142060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously.
Study NCT03570125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prolon
Description: The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS). In case the PROLON product will be unavailable at the time of the project we will design fasting mimicking diet without the usage of specifically designed commercial product
Study NCT00722995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy is a restrictive procedure for the treatment for morbid obesity
Study NCT00722995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass
Description: Laparoscopic gastric bypass is a restrictive and difficult absorption procedure for the treatment of morbid obesity
Study NCT00507741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide
Description: Part A: Induction Phase: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance Phase: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting. Part B: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
Study NCT00507741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertafolide
Study NCT02125032 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial low voltage pulsed electromagnetic fields (T-PEMF)
Study NCT02125032 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transcranial low voltage electromagnetic fields
Study NCT01674933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duraphat® Fluoride Varnish
Description: 0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
Study NCT01674933 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: includes supervised toothbrushing, distribution of toothbrushes and toothpaste and oral health advice given at nursery school.
Study NCT02546063 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Smartphone App
Description: The GoCARB system is a smartphone application designed to support type 1 diabetic patients with carbohydrate counting by providing automatic, accurate and near real-time CHO estimation for non-packed foods.
Study NCT03070184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise capacity VO2 max determination
Description: Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.